Scholarlink

Purpose <p>High-risk neuroblastomas carry a poor prognosis, and the role of the immunosuppressive glycoprotein CD200 in this disease remains unclear. In this study, we investigated the role of CD200 expression.</p> Methods <p>We retrospectively analyzed CD200 expression in 45 neuroblastoma specimens using immunohistochemistry (IHC). Its association with clinicopathological features, patient survival, and tumor-infiltrating lymphocytes (TILs) density was evaluated. Changes in CD200 expression during chemotherapy were examined in the high-risk subgroup. The functional role of CD200 in chemosensitivity was assessed in vitro using siRNA-mediated silencing in SH-SY5Y and IMR-32 neuroblastoma cell lines.</p> Results <p>High CD200 expression was significantly associated with advanced-stage disease, recurrence, and poor overall survival (5-year OS: 57.3% vs. 100% in low-CD200, <i>p</i> = 0.007). High-CD200 tumors showed significantly reduced infiltration of CD4 + and CD8 + T cells. In high-risk patients, persistently high or increased post-chemotherapy CD200 expression was correlated with 100% recurrence and mortality. In vitro, CD200 silencing significantly enhanced the cytotoxic effects of cisplatin.</p> Conclusion <p>CD200 is a strong negative prognostic biomarker in neuroblastoma, associated with an immunosuppressive tumor microenvironment and chemoresistance. It represents a promising candidate for treatment stratification and a potential therapeutic target for improving outcomes in high-risk patients.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

CD200 expression predicts poor prognosis in neuroblastoma: a potential biomarker for treatment stratification—a retrospective cohort study

  • 期刊论文

  • 发表日期：

    2026年1月22日

查看全文
  • Yasuhiro Kuroda,
  • Shogo Zuo,
  • Taichi Terai,
  • Shintaro Miyao,
  • Kota Nakamura,
  • Hiromichi Kanehiro,
  • Makiko Yoshida,
  • Tadashi Hatakeyama,
  • Masayuki Sho

摘要

Purpose

High-risk neuroblastomas carry a poor prognosis, and the role of the immunosuppressive glycoprotein CD200 in this disease remains unclear. In this study, we investigated the role of CD200 expression.

Methods

We retrospectively analyzed CD200 expression in 45 neuroblastoma specimens using immunohistochemistry (IHC). Its association with clinicopathological features, patient survival, and tumor-infiltrating lymphocytes (TILs) density was evaluated. Changes in CD200 expression during chemotherapy were examined in the high-risk subgroup. The functional role of CD200 in chemosensitivity was assessed in vitro using siRNA-mediated silencing in SH-SY5Y and IMR-32 neuroblastoma cell lines.

Results

High CD200 expression was significantly associated with advanced-stage disease, recurrence, and poor overall survival (5-year OS: 57.3% vs. 100% in low-CD200, p = 0.007). High-CD200 tumors showed significantly reduced infiltration of CD4 + and CD8 + T cells. In high-risk patients, persistently high or increased post-chemotherapy CD200 expression was correlated with 100% recurrence and mortality. In vitro, CD200 silencing significantly enhanced the cytotoxic effects of cisplatin.

Conclusion

CD200 is a strong negative prognostic biomarker in neuroblastoma, associated with an immunosuppressive tumor microenvironment and chemoresistance. It represents a promising candidate for treatment stratification and a potential therapeutic target for improving outcomes in high-risk patients.